Clinical efficacy of anticoagulation therapy in early-onset severe preeclampsia with coagulation dysfunction
早发型重度子痫前期凝血功能变化及抗凝治疗的临床成效研究

摘要

目的 研究抗凝治疗对早发型重度子痫前期凝血功能变化的影响与临床成效。方法 选择2023-2025年80例早发型重度子痫前期患者进行医学观察，随机分为一般治疗组与抗凝治疗组，分别实施常规治疗、常规与抗凝联合治疗的方案，对比两组患者的治疗情况。结果 治疗后，抗凝治疗组凝血酶原时间、活化部分凝血活酶时间、纤维蛋白原、D-二聚体等指标改善幅度显著于一般治疗组，P<0.05；抗凝治疗组顺产分娩率高于一般治疗组，P<0.05。且早产、胎儿生长受限、新生儿窒息等情况均优于一般治疗组，P<0.05。结论 早发型重度子痫前期的患者，可通过抗凝治疗改善凝血功能，改善母婴结局，值得推广。

Abstract

Objective To investigate the impact of anticoagulant therapy on coagulation function changes and clinical outcomes in patients with early-onset severe preeclampsia.
Methods A total of 80 patients with early-onset severe preeclampsia from 2023 to 2025 were randomly assigned to either standard treatment or anticoagulant therapy, receiving either conventional treatment or combined conventional-anticoagulant therapy respectively.
Results After treatment, the anticoagulant therapy group showed significantly better improvements in prothrombin time, activated partial thromboplastin time, fibrinogen, and D-dimer levels compared to the conventional treatment group (P <0.05). Additionally, the anticoagulant therapy group had a higher rate of vaginal delivery (P <0.05). The outcomes for preterm birth, fetal growth restriction, and neonatal asphyxia were also superior in the anticoagulant therapy group (P <0.05).
Conclusion   Anticoagulant therapy can effectively improve coagulation function and maternal-fetal outcomes in patients with early-onset severe preeclampsia, making it a clinically valuable treatment option worthy of promotion.